September 2026 quarter: consolidated revenue up 19.6%, profit after tax up 27.4%
LALPATHLAB · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 3.9 pts more than Nifty Smallcap 250 and 4.2 pts more than its Healthcare Service Provider peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
For the consolidated quarter ended September 30, 2026, revenue was INR 8,739 million versus INR 7,306 million and profit after tax INR 1,939 million versus INR 1,522 million in the year-ago quarter, up 19.6% and 27.4%. The margin before interest, tax, depreciation and amortisation rose from 30.7% to 32.1%. 2025 EPS was restated for bonus shares. An INR 5 interim dividend was declared; up to INR 49.5 crore overseas investment was approved.
Profit growth and a wider margin support sentiment. The INR 5 dividend helps shareholders, but overseas expansion may raise cash outflow.
The filed figures for this quarter have not reached us in XBRL yet, so there is nothing to compute here; the read above is the AI's, from the document. The table appears the moment the figures land.